Recombinant interleukin-12, but not granulocyte-colony stimulating factor, improves survival in lethally irradiated nonhuman primates in the absence of supportive care: Evidence for the development of a frontline radiation medical countermeasure

2014 ◽  
Vol 89 (9) ◽  
pp. 868-873 ◽  
Author(s):  
Zoya Gluzman-Poltorak ◽  
Vladimir Vainstein ◽  
Lena A. Basile
Keyword(s):  
Supportive Care ◽  
Nonhuman Primates ◽  
Interleukin 12 ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Stimulating Factor

DOWNREGULATION OF BOTH INTERLEUKIN-12 AND INTERLEUKIN-2 IN HEART ALLOGRAFTS BY PRETRANSPLANT HOST TREATMENT WITH GRANULOCYTE COLONY-STIMULATING FACTOR AND TACROLIMUS

Cytokine ◽  
2002 ◽  
Vol 18 (3) ◽  
pp. 164-167 ◽  
Author(s):  
Hiroyuki Egi ◽  
Keisuke Hayamizu ◽  
Teruhiko Kitayama ◽  
Ichiro Ohmori ◽  
Masazumi Okajima ◽  
...  
Keyword(s):  
Interleukin 2 ◽  
Interleukin 12 ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Stimulating Factor

scholarly journals Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children’s Oncology Group

Blood ◽  
2013 ◽  
Vol 121 (18) ◽  
pp. 3573-3577 ◽  
Author(s):  
Lillian Sung ◽  
Richard Aplenc ◽  
Todd A. Alonzo ◽  
Robert B. Gerbing ◽  
Thomas Lehrnbecher ◽  
...  
Keyword(s):  
Supportive Care ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Oncology Group ◽  
Infection Rates ◽  
Key Points ◽  
Pediatric Aml ◽  
Stimulating Factor ◽  
Related Mortality ◽  
Systemic Antibacterial

Key Points Systemic antibacterial and granulocyte colony-stimulating factor prophylaxis appear to reduce bacterial infection rates. Mandatory hospitalization during profound neutropenia did not reduce infection or significantly reduce nonrelapse-related mortality.

scholarly journals Successful Treatment of Cisplatin Overdose with Plasma Exchange

2010 ◽  
Vol 2010 ◽  
pp. 1-4 ◽  
Author(s):  
Yasuhiro Yamada ◽  
Yoshiaki Ikuta ◽  
Kisato Nosaka ◽  
Nobutomo Miyanari ◽  
Naoko Hayashi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Adjuvant Therapy ◽  
Supportive Care ◽  
Plasma Exchange ◽  
Bone Marrow Suppression ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Subtotal Esophagectomy ◽  
Intravenous Hydration ◽  
Stimulating Factor

Accidental cisplatin overdose has been occurring with an increasing frequency due to expanding usage of the agent. However, the optimal strategy to treat such patients remains to be established. Here, we report a case of large cisplatin overdose, successfully managed by plasma exchange, intravenous hydration, granulocyte colony-stimulating factor (G-CSF) administration, and other supportive care. A 67-year-old man with esophageal carcinoma received a large cisplatin overdose of 240 , when he received adjuvant therapy following subtotal esophagectomy. On day 4, he experienced frank cisplatin toxicities and emergency plasma exchange was initiated. With 7 cycles of plasma exchange, the cisplatin concentration decreased from 2,350 to 110 ng/mL. Severe bone marrow suppression with high fever ensued on day 10, which was successfully treated with G-CSF and antibiotics. Despite moderate hearing sense reduction, he recovered without significant complications. Immediate plasma exchange with hydration and other care was efficacious in quickly lowering cisplatin concentrations.

scholarly journals NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020

2020 ◽  
Vol 18 (1) ◽  
pp. 12-22 ◽  
Author(s):  
Pamela Sue Becker ◽  
Elizabeth A. Griffiths ◽  
Laura M. Alwan ◽  
Kimo Bachiashvili ◽  
Anna Brown ◽  
...  
Keyword(s):  
Growth Factors ◽  
Febrile Neutropenia ◽  
Supportive Care ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Hematopoietic Growth Factors ◽  
Appropriate Use ◽  
Nccn Guidelines ◽  
Prevention And Treatment ◽  
Stimulating Factor

Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.

Sign in / Sign up

Export Citation Format

Share Document